Get With The Guidelines-Heart Failure Hospital Participation and its Association with Guideline-Directed Medical Therapy and Outcomes

This retrospective analysis of over 1.2 million Medicare beneficiaries demonstrates that hospital participation in the Get With The Guidelines-Heart Failure program is associated with increased adherence to guideline-directed medical therapy and significantly reduced all-cause mortality, though it did not significantly impact heart failure readmission rates.

The Gist

Imagine the healthcare system as a massive, sprawling network of schools. Some schools are part of a special "National Excellence Program" (let's call it GWTG-HF), while others operate on their own. The goal of this program is to make sure every student (patient) gets the very best, most up-to-date textbooks and study guides (medications) to help them succeed.

This research paper is like a report card comparing the students who went to schools in the "Excellence Program" against those who went to schools that never joined.

The Big Question

Heart failure is a serious condition where the heart struggles to pump blood. Doctors have a specific "recipe" of life-saving medicines (called GDMT) that are proven to help patients live longer and feel better. However, in the real world, not every doctor or hospital follows this recipe perfectly. Sometimes they forget a step, or they don't give the full dose.

The researchers wanted to know: Does joining this "Excellence Program" actually help hospitals get better at following the recipe and saving lives?

How They Did the Study (The "Time Travel" Analogy)

Instead of just looking at a snapshot of one day, the researchers used a clever method called a "Multiple Baseline Time Series."

Think of it like this: Imagine you have 2,000 schools.

1. Some schools join the "Excellence Program" in 2013.
2. Some join in 2015.
3. Some join in 2018.
4. Some never join at all.

The researchers watched each school before they joined, while they were in the program, and compared them to the schools that never joined. This allowed them to see if the schools actually improved because they joined, rather than just because medicine was getting better everywhere over time.

They looked at over 1.2 million Medicare patients (seniors) who were hospitalized for heart failure between 2013 and 2021.

The Results: What Happened?

1. The "Recipe" Was Followed Better
When hospitals joined the program, they got much better at prescribing the right medicines.

• The Score: They created a "Scorecard" (0 to 14 points) based on how many medicines the patient got and if the dose was strong enough.
• The Improvement: Patients treated at "Program" hospitals had a higher score. It was like a student who, after joining the program, started using the latest study guides and getting full credit for every assignment.
• Specifics: They were more likely to get Beta-blockers, MRA, and RASI (the core ingredients of the heart failure recipe). Interestingly, they didn't see a huge jump in the newest, fanciest ingredient (ARNI) right away, likely because it was expensive and new at the time.

2. The "Survival" Rate Went Up
This is the most important part.

• Patients at "Program" hospitals were less likely to die within 30 days, 90 days, and even one year after leaving the hospital.
• It's like saying, "Students who used the new study guides were more likely to graduate and less likely to drop out."

3. The "Readmission" Rate Stayed the Same
Here is a twist: Even though fewer people died, the number of people coming back to the hospital for heart failure didn't change much.

• The Analogy: Imagine a car repair shop. The "Program" shops fixed the engine so well that the car didn't break down completely (death), but the car still had some minor rattles that made it come back for a tune-up (readmission). The program saved lives, but it didn't stop every single future hospital visit.

Why Does This Matter?

The study found that hospitals that joined the program were often larger and better funded to begin with (like big, well-equipped universities). However, even after accounting for those advantages, the program itself seemed to make a difference.

The researchers suggest that the program acts like a coach. It doesn't just give you a playbook; it gives you:

• Regular check-ins (workshops).
• A way to see how you compare to other schools (benchmarks).
• Tools to make sure you don't miss a step.

The Bottom Line

Joining the Get With The Guidelines-Heart Failure program is like a school deciding to adopt a proven, high-quality curriculum. The study shows that when hospitals do this:

1. They are better at giving patients the right life-saving medicines.
2. Their patients live longer.

The authors conclude that while we still have work to do (especially for smaller, rural hospitals that haven't joined yet), these structured quality programs are a powerful tool to keep our hearts beating stronger for longer.

Technical Summary

1. Problem Statement

Despite robust clinical evidence supporting Guideline-Directed Medical Therapy (GDMT) for Heart Failure with Reduced Ejection Fraction (HFrEF), real-world adoption remains suboptimal. The Get With The Guidelines–Heart Failure (GWTG-HF) program is a national quality improvement initiative designed to bridge this gap. However, while previous studies showed that GWTG-HF participating hospitals generally have higher process-of-care metrics, there was a lack of evidence evaluating whether joining the registry (the intervention) causally leads to improvements in GDMT intensity and clinical outcomes within those specific hospitals over time. This study aimed to fill that gap by assessing the association between hospital enrollment in GWTG-HF and subsequent changes in care quality and patient survival.

2. Methodology

Study Design

• Approach: A retrospective, quasi-experimental multiple baseline time series analysis.
• Rationale: This design treats each hospital as its own control (pre-enrollment vs. post-enrollment) while using non-participating hospitals as concurrent controls. This allows for the separation of the intervention effect from secular trends (national improvements over time) and accommodates the staggered enrollment of hospitals into the registry.
• Data Source: Linked Medicare Fee-for-Service claims (Parts A and D) from January 1, 2013, to December 31, 2021.

Study Population

• Inclusion: Medicare beneficiaries hospitalized with HFrEF (defined by ICD codes for systolic heart failure).
• Exclusion: Patients with heart transplants, LVADs, advanced CKD (Stage 4/5), dialysis dependence, in-hospital death, hospice discharge, or transfer to another acute care facility.
• Cohort: 1,274,863 beneficiaries.
  • GWTG-HF Group: 122,554 patients (9.6%) treated at hospitals that enrolled during the study period.
  • Control Group: 681,935 patients (53.5%) treated at hospitals that never participated.
  • Note: Patients at hospitals that enrolled before the study period or disenrolled were excluded to ensure a clear pre/post comparison.

Exposure

• Primary Exposure: Hospitalization at a facility with active GWTG-HF participation at the time of admission. Hospitals contributed data to the "non-GWTG" group prior to enrollment and the "GWTG" group after enrollment.

Outcomes

• Primary Outcome: A composite GDMT Score at 90 days post-discharge.
  • Components: Beta-blockers, Renin-Angiotensin System Inhibitors (RASI: ACEi/ARB/ARNI), and Mineralocorticoid Receptor Antagonists (MRA).
  • Scoring: Based on initiation (2 points) and dose intensity (up to 2 points per drug class for RASI/BB, up to 4 for ARNI). Total range: 0–14.
  • Note: SGLT2 inhibitors were excluded from the primary score as they were not approved for HF for most of the study period.
• Secondary Outcomes:
  • Individual medication fills (Beta-blockers, RASI, MRA, ARNI).
  • Achievement of ≥50% target doses.
  • Clinical outcomes: 30-day, 90-day, and 1-year all-cause mortality; HF readmission; all-cause readmission.

Statistical Analysis

• Model: Mixed-effects models with a random intercept for the discharging hospital to account for baseline heterogeneity.
• Adjustments: Patient demographics (age, sex, race, rurality, Social Vulnerability Index), comorbidities, and seasonal variation.
• Trend Analysis: Tested for parallel pre-intervention trends between groups. Found no significant difference, validating the assumption of parallel trends.
• Sensitivity Analyses: Included models with different baseline slopes, exclusion of patients dying before follow-up, and adjustments for hospital characteristics.

3. Key Contributions

• Longitudinal Causal Inference: Unlike cross-sectional studies, this analysis isolates the impact of joining the registry by comparing hospitals before and after enrollment against a control group, controlling for secular trends.
• Granular GDMT Assessment: Utilization of a composite score that accounts for both initiation and dose intensity, providing a more nuanced view of care quality than simple binary "use/no-use" metrics.
• Real-World Generalizability: The study leverages a massive national dataset (Medicare) covering over 1.2 million hospitalizations, reflecting diverse healthcare settings across the US.
• Differentiation of Outcomes: The study distinguishes between process measures (medication adherence) and hard clinical endpoints (mortality vs. readmission), offering insight into which aspects of care are most responsive to quality improvement initiatives.

4. Results

Baseline Characteristics

• Patients in GWTG-HF hospitals were slightly younger and less likely to be rural compared to non-GWTG hospitals.
• GWTG-HF hospitals were significantly larger (>400 beds), more likely to be teaching hospitals, and had higher CMS quality ratings.
• Crucially, pre-admission GDMT scores and medication usage were statistically similar between the two groups (Median score 3.0 for both), indicating comparable baseline care quality.

GDMT Utilization (Process Measures)

• Composite Score: Hospitalization at a GWTG-HF facility was associated with a significantly higher 90-day GDMT score compared to non-participating hospitals (+0.15 points; 95% CI 0.12–0.18; p<0.001).
• Medication Specifics:
  • Beta-blockers: Higher odds of use (OR 1.07) and achieving ≥50% target dose (OR 1.08).
  • RASI: Higher odds of use (OR 1.02).
  • MRA: Significantly higher odds of use (OR 1.13).
  • ARNI: No significant difference in initiation (OR 1.02), likely due to late guideline adoption and cost barriers during the study period.
• Target Doses: While GWTG hospitals improved beta-blocker dosing, they were less likely to achieve ≥50% target doses for RASI compared to controls (OR 0.96), suggesting complex challenges in uptitration.

Clinical Outcomes

• Mortality: GWTG-HF participation was associated with a statistically significant reduction in all-cause mortality:
  • 30 days: OR 0.95 (95% CI 0.92–0.98)
  • 90 days: OR 0.97 (95% CI 0.95–0.99)
  • 1 year: OR 0.97 (95% CI 0.95–0.99)
• Readmissions: No significant difference was found in HF readmission or all-cause readmission rates at 30, 90, or 365 days.
• Mediation Analysis: When the 90-day GDMT score was added as a covariate in the mortality model, the association between GWTG participation and mortality became non-significant, suggesting that improved medication adherence mediates the survival benefit.

5. Significance and Conclusion

Significance

• Validation of Quality Programs: The study provides strong evidence that structured quality improvement programs like GWTG-HF are effective in translating guidelines into practice, specifically increasing the intensity of GDMT.
• Survival Benefit: The modest but significant reduction in mortality underscores the clinical value of these programs. The finding that GDMT intensity mediates this survival benefit reinforces the importance of medication optimization in HFrEF management.
• Disparity Awareness: The study highlights that GWTG-HF participation is currently skewed toward larger, urban, teaching hospitals. Rural and smaller hospitals (which serve high-risk populations) are underrepresented, pointing to a need for targeted recruitment to ensure equitable care improvements.

Limitations

• Observational Nature: Despite robust statistical controls, unmeasured confounding (e.g., institutional culture of quality improvement) may exist. Hospitals that join may already be more motivated to improve.
• Data Constraints: Administrative claims data cannot capture reasons for non-adherence (e.g., intolerance, cost, patient preference) or device therapies.
• Coding Accuracy: Potential misclassification of HFrEF based on ICD codes.

Conclusion
Hospital participation in the GWTG-HF program is associated with higher intensity of guideline-directed medical therapy and lower post-discharge mortality for patients with HFrEF. These findings support the continued expansion and refinement of structured quality improvement initiatives to drive the adoption of evidence-based therapies, particularly in under-resourced and rural healthcare settings.